Identification

Name
Cholestyramine
Accession Number
DB01432
Type
Small Molecule
Groups
Approved
Description

Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.

Synonyms
  • Cholestyramine resin
  • Colestyramine
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CholestyraminePowder, for suspension4 gOralSorres Pharma Inc1998-02-172010-10-06Canada
CholestyraminePowder, for suspension4 gOralSorres Pharma Inc1998-02-172010-10-19Canada
Cholestyramine-odanPowder, for suspension4 gOralOdan Laboratories Ltd2016-12-23Not applicableCanada
OlestyrPowder, for suspension4 gOralPharmascience Inc1996-03-15Not applicableCanada
OlestyrPowder, for suspension4 gOralPharmascience Inc1993-12-31Not applicableCanada
Questran Light Pws 4gm/pckPowder, for solution4 gOralBristol Labs Division Of Bristol Myers Squibb1991-12-312005-08-01Canada
Questran Pwr 378gm/canPowder, for solution4 gOralBristol Labs Division Of Bristol Myers Squibb1985-12-312005-08-01Canada
Questran Pwr 4gm/9gmPowder, for solution4 gOralBristol Labs Division Of Bristol Myers Squibb1979-12-312005-08-01Canada
Questran Tab 1gmTablet1 gOralBristol Myers Squibb1993-12-311999-08-09Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-cholestyramine LightKit; Powder4 gOralAltimed Pharma Inc.1994-12-311999-09-17Canada
CholestyraminePowder, for suspension4 g/9gOralPhysicians Total Care, Inc.2010-03-22Not applicableUs
CholestyraminePowder, for suspension4 g/9gOralEon Labs, Inc.1996-08-15Not applicableUs
CholestyraminePowder, for suspension4 g/9gOralPar Pharmaceutical2005-09-15Not applicableUs
CholestyraminePowder, for suspension4 g/9gOralUpsher Smith Laboratories2012-01-05Not applicableUs
CholestyraminePowder, for suspension4 g/9gOralGolden State Medical Supply2005-09-152017-10-26Us
CholestyraminePowder, for suspension4 g/5.5gOralCadila Pharnmaceuticals2017-06-08Not applicableUs
CholestyraminePowder, for suspension4 g/5gOralPhysicians Total Care, Inc.2006-02-08Not applicableUs
CholestyraminePowder, for suspension4 g/5gOralPar Pharmaceutical2005-09-15Not applicableUs
CholestyraminePowder, for suspension4 g/5.5gOralZydus Pharmaceuticals Usa, Inc.2017-06-08Not applicableUs
International/Other Brands
Cholybar / Locholest / Locholest light / Questran Light
Categories
UNII
4B33BGI082
CAS number
11041-12-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.

Structured Indications
Pharmacodynamics

Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum. Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.

Mechanism of action

Cholestyramine binds bile in the gastrointestinal tract to prevent its reabsorption. The resin is a strong anion exchange resin, which means that it can exchange its chloride anions with anionic bile acids in the gastrointestinal tract and bind them strongly in the resin matrix. The functional group of the anion exchange resin is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer.

TargetActionsOrganism
ABile acids
binder
Human
Absorption

Not absorbed from the gastrointestinal tract following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Bile acids

Route of elimination

Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces.

Half life

6 minutes

Clearance
Not Available
Toxicity

Overdose may result in blockage of intestine or stomach.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneCholestyramine can cause a decrease in the absorption of 16-Bromoepiandrosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
19-norandrostenedioneCholestyramine can cause a decrease in the absorption of 19-norandrostenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
5-androstenedioneCholestyramine can cause a decrease in the absorption of 5-androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
AceclofenacCholestyramine can cause a decrease in the absorption of Aceclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AcemetacinCholestyramine can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
AcenocoumarolCholestyramine can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetaminophenCholestyramine can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetyldigitoxinCholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetyldigoxinCholestyramine can cause a decrease in the absorption of Acetyldigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Acetylsalicylic acidCholestyramine can cause a decrease in the absorption of Acetylsalicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AdapaleneCholestyramine can cause a decrease in the absorption of Adapalene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclofenacCholestyramine can cause a decrease in the absorption of Alclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
AlclometasoneCholestyramine can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AldosteroneCholestyramine can cause a decrease in the absorption of Aldosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
AlminoprofenCholestyramine can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium clofibrateCholestyramine can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AmcinonideCholestyramine can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmiodaroneThe bioavailability of Amiodarone can be decreased when combined with Cholestyramine.Approved, Investigational
AndrographolideCholestyramine can cause a decrease in the absorption of Andrographolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AndrostenedioneCholestyramine can cause a decrease in the absorption of Androstenedione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Illicit
AnecortaveCholestyramine can cause a decrease in the absorption of Anecortave resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
anecortave acetateCholestyramine can cause a decrease in the absorption of anecortave acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AnisodamineCholestyramine can cause a decrease in the absorption of Anisodamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AntipyrineCholestyramine can cause a decrease in the absorption of Antipyrine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ApocyninCholestyramine can cause a decrease in the absorption of Apocynin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ApremilastCholestyramine can cause a decrease in the absorption of Apremilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtamestaneCholestyramine can cause a decrease in the absorption of Atamestane resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Cholestyramine.Approved
AzapropazoneCholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
AzelastineCholestyramine can cause a decrease in the absorption of Azelastine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BalsalazideCholestyramine can cause a decrease in the absorption of Balsalazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Beclomethasone dipropionateCholestyramine can cause a decrease in the absorption of Beclomethasone dipropionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BendazacCholestyramine can cause a decrease in the absorption of Bendazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BendroflumethiazideCholestyramine can cause a decrease in the absorption of Bendroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BenorilateCholestyramine can cause a decrease in the absorption of Benorilate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BenoxaprofenCholestyramine can cause a decrease in the absorption of Benoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
BenzydamineCholestyramine can cause a decrease in the absorption of Benzydamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BetamethasoneCholestyramine can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
BevoniumCholestyramine can cause a decrease in the absorption of Bevonium resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BezafibrateCholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacCholestyramine can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BucillamineCholestyramine can cause a decrease in the absorption of Bucillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BudesonideCholestyramine can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BufexamacCholestyramine can cause a decrease in the absorption of Bufexamac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BumadizoneCholestyramine can cause a decrease in the absorption of Bumadizone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BumetanideCholestyramine can cause a decrease in the absorption of Bumetanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CalcidiolThe serum concentration of Calcidiol can be decreased when it is combined with Cholestyramine.Approved, Nutraceutical
CalcipotriolThe serum concentration of Calcipotriol can be decreased when it is combined with Cholestyramine.Approved
Carbaspirin calciumCholestyramine can cause a decrease in the absorption of Carbaspirin calcium resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
CarprofenCholestyramine can cause a decrease in the absorption of Carprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved, Withdrawn
CastanospermineCholestyramine can cause a decrease in the absorption of Castanospermine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CelecoxibCholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Cholestyramine.Approved
ChloroquineCholestyramine can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorothiazideCholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Cholestyramine.Investigational, Withdrawn
ChlortetracyclineCholestyramine can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorthalidoneCholestyramine can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidCholestyramine can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateCholestyramine can cause a decrease in the absorption of Choline magnesium trisalicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCholestyramine can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CiprofibrateCholestyramine can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolCholestyramine can cause a decrease in the absorption of Clobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Clobetasol propionateCholestyramine can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClobetasoneCholestyramine can cause a decrease in the absorption of Clobetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClocortoloneCholestyramine can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClofibrateCholestyramine can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClofibrideCholestyramine can cause a decrease in the absorption of Clofibride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ClonixinCholestyramine can cause a decrease in the absorption of Clonixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClorindioneCholestyramine can cause a decrease in the absorption of Clorindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Cholestyramine.Approved
Cortexolone 17α-propionateCholestyramine can cause a decrease in the absorption of Cortexolone 17α-propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
CorticosteroneCholestyramine can cause a decrease in the absorption of Corticosterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Cortisone acetateCholestyramine can cause a decrease in the absorption of Cortisone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CurcuminCholestyramine can cause a decrease in the absorption of Curcumin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
CyclopenthiazideCholestyramine can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CymarinCholestyramine can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DeferasiroxThe serum concentration of Deferasirox can be decreased when it is combined with Cholestyramine.Approved, Investigational
DeflazacortCholestyramine can cause a decrease in the absorption of Deflazacort resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DemeclocyclineCholestyramine can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeslanosideCholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Cholestyramine.Approved
DesonideCholestyramine can cause a decrease in the absorption of Desonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DesoximetasoneCholestyramine can cause a decrease in the absorption of Desoximetasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Desoxycorticosterone acetateCholestyramine can cause a decrease in the absorption of Desoxycorticosterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Desoxycorticosterone PivalateCholestyramine can cause a decrease in the absorption of Desoxycorticosterone Pivalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Vet Approved
DexamethasoneCholestyramine can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateCholestyramine can cause a decrease in the absorption of Dexamethasone isonicotinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
DiclofenacCholestyramine can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
DicoumarolCholestyramine can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Cholestyramine.Approved, Investigational
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Cholestyramine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cholestyramine.Approved, Investigational
DifenpiramideCholestyramine can cause a decrease in the absorption of Difenpiramide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DiflorasoneCholestyramine can cause a decrease in the absorption of Diflorasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflunisalCholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DifluocortoloneCholestyramine can cause a decrease in the absorption of Difluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
DifluprednateCholestyramine can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinCholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DigoxinCholestyramine can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Digoxin Immune Fab (Ovine)Cholestyramine can cause a decrease in the absorption of Digoxin Immune Fab (Ovine) resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DihydrotachysterolThe serum concentration of Dihydrotachysterol can be decreased when it is combined with Cholestyramine.Approved
DiphenadioneCholestyramine can cause a decrease in the absorption of Diphenadione resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DoxercalciferolThe serum concentration of Doxercalciferol can be decreased when it is combined with Cholestyramine.Approved
DoxycyclineCholestyramine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Cholestyramine.Approved
DroxicamCholestyramine can cause a decrease in the absorption of Droxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
DuvelisibCholestyramine can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
E-6201Cholestyramine can cause a decrease in the absorption of E-6201 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EpirizoleCholestyramine can cause a decrease in the absorption of Epirizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EquileninCholestyramine can cause a decrease in the absorption of Equilenin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
EquilinCholestyramine can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Cholestyramine.Approved, Nutraceutical
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Cholestyramine.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Cholestyramine.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Cholestyramine.Approved
EstroneCholestyramine can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Cholestyramine.Approved
Etacrynic acidCholestyramine can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EtanerceptCholestyramine can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthenzamideCholestyramine can cause a decrease in the absorption of Ethenzamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cholestyramine.Approved
Ethyl biscoumacetateCholestyramine can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Cholestyramine.Approved
EtodolacCholestyramine can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
EtofenamateCholestyramine can cause a decrease in the absorption of Etofenamate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EtofibrateCholestyramine can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Cholestyramine.Approved, Investigational
EtoricoxibCholestyramine can cause a decrease in the absorption of Etoricoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Evening primrose oilCholestyramine can cause a decrease in the absorption of Evening primrose oil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ExisulindCholestyramine can cause a decrease in the absorption of Exisulind resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EzetimibeCholestyramine can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FelbinacCholestyramine can cause a decrease in the absorption of Felbinac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FenbufenCholestyramine can cause a decrease in the absorption of Fenbufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenofibrateCholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Fenofibric acidCholestyramine can cause a decrease in the absorption of Fenofibric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FenoprofenCholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FentiazacCholestyramine can cause a decrease in the absorption of Fentiazac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FeprazoneCholestyramine can cause a decrease in the absorption of Feprazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferulic acidCholestyramine can cause a decrease in the absorption of Ferulic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FloctafenineCholestyramine can cause a decrease in the absorption of Floctafenine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluasteroneCholestyramine can cause a decrease in the absorption of Fluasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
FludrocortisoneCholestyramine can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluindioneCholestyramine can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
FlumethasoneCholestyramine can cause a decrease in the absorption of Flumethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
FlunisolideCholestyramine can cause a decrease in the absorption of Flunisolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FlunixinCholestyramine can cause a decrease in the absorption of Flunixin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
FlunoxaprofenCholestyramine can cause a decrease in the absorption of Flunoxaprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Fluocinolone AcetonideCholestyramine can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
FluocinonideCholestyramine can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FluocortoloneCholestyramine can cause a decrease in the absorption of Fluocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluorometholoneCholestyramine can cause a decrease in the absorption of Fluorometholone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneCholestyramine can cause a decrease in the absorption of Fluprednidene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
FluprednisoloneCholestyramine can cause a decrease in the absorption of Fluprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlurandrenolideCholestyramine can cause a decrease in the absorption of Flurandrenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlurbiprofenCholestyramine can cause a decrease in the absorption of Flurbiprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Fluticasone furoateCholestyramine can cause a decrease in the absorption of Fluticasone furoate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Fluticasone propionateCholestyramine can cause a decrease in the absorption of Fluticasone propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Cholestyramine.Approved
FormestaneCholestyramine can cause a decrease in the absorption of Formestane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
FurosemideCholestyramine can cause a decrease in the absorption of Furosemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
GemfibrozilCholestyramine can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Cholestyramine.Approved, Investigational
GitoformateCholestyramine can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GuacetisalCholestyramine can cause a decrease in the absorption of Guacetisal resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
HalcinonideCholestyramine can cause a decrease in the absorption of Halcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HE3286Cholestyramine can cause a decrease in the absorption of HE3286 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Cholestyramine.Withdrawn
HigenamineCholestyramine can cause a decrease in the absorption of Higenamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
HydrochlorothiazideCholestyramine can cause a decrease in the absorption of Hydrochlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
HydrocortisoneCholestyramine can cause a decrease in the absorption of Hydrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
HydroflumethiazideCholestyramine can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IbuprofenCholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbuproxamCholestyramine can cause a decrease in the absorption of Ibuproxam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IcatibantCholestyramine can cause a decrease in the absorption of Icatibant resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Imidazole salicylateCholestyramine can cause a decrease in the absorption of Imidazole salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
IndapamideCholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndobufenCholestyramine can cause a decrease in the absorption of Indobufen resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
IndomethacinCholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IndoprofenCholestyramine can cause a decrease in the absorption of Indoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IsoxicamCholestyramine can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
IstaroximeCholestyramine can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
KebuzoneCholestyramine can cause a decrease in the absorption of Kebuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
KetoprofenCholestyramine can cause a decrease in the absorption of Ketoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
KetorolacCholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Lanatoside CCholestyramine can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
LeflunomideThe serum concentration of the active metabolites of Leflunomide can be reduced when Leflunomide is used in combination with Cholestyramine resulting in a loss in efficacy.Approved, Investigational
Levomefolic acidThe serum concentration of Levomefolic acid can be decreased when it is combined with Cholestyramine.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Cholestyramine.Approved, Investigational
LisofyllineCholestyramine can cause a decrease in the absorption of Lisofylline resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
LomitapideCholestyramine can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LonazolacCholestyramine can cause a decrease in the absorption of Lonazolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
LornoxicamCholestyramine can cause a decrease in the absorption of Lornoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolCholestyramine can cause a decrease in the absorption of Loteprednol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LoxoprofenCholestyramine can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LumiracoxibCholestyramine can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Cholestyramine.Investigational
Magnesium salicylateCholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolCholestyramine can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ME-609Cholestyramine can cause a decrease in the absorption of ME-609 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Meclofenamic acidCholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Cholestyramine.Approved, Investigational
MedrysoneCholestyramine can cause a decrease in the absorption of Medrysone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Mefenamic acidCholestyramine can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MelengestrolCholestyramine can cause a decrease in the absorption of Melengestrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
MeloxicamCholestyramine can cause a decrease in the absorption of Meloxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
MesalazineCholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Cholestyramine.Approved
MetamizoleCholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Cholestyramine.Experimental
MethotrexateCholestyramine can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethyclothiazideCholestyramine can cause a decrease in the absorption of Methyclothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethylprednisoloneCholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
MetildigoxinCholestyramine can cause a decrease in the absorption of Metildigoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MetolazoneCholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MinocyclineCholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MizoribineCholestyramine can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
MofebutazoneCholestyramine can cause a decrease in the absorption of Mofebutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
MometasoneCholestyramine can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Mycophenolate mofetilCholestyramine can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine.Approved
NabumetoneCholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NafamostatCholestyramine can cause a decrease in the absorption of Nafamostat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftifineCholestyramine can cause a decrease in the absorption of Naftifine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NaproxenCholestyramine can cause a decrease in the absorption of Naproxen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
NCX 1022Cholestyramine can cause a decrease in the absorption of NCX 1022 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NepafenacCholestyramine can cause a decrease in the absorption of Nepafenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NiacinCholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
NifenazoneCholestyramine can cause a decrease in the absorption of Nifenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Niflumic AcidCholestyramine can cause a decrease in the absorption of Niflumic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NimesulideCholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
NitroaspirinCholestyramine can cause a decrease in the absorption of Nitroaspirin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Cholestyramine.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Cholestyramine.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Cholestyramine.Approved
OleandrinCholestyramine can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Oleoyl-estroneCholestyramine can cause a decrease in the absorption of Oleoyl-estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OlopatadineCholestyramine can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OlsalazineCholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OrgoteinCholestyramine can cause a decrease in the absorption of Orgotein resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
OuabainCholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OxaprozinCholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OxyphenbutazoneCholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
ParamethasoneCholestyramine can cause a decrease in the absorption of Paramethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParecoxibCholestyramine can cause a decrease in the absorption of Parecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine.Approved, Investigational
ParthenolideCholestyramine can cause a decrease in the absorption of Parthenolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PeruvosideCholestyramine can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PhenindioneCholestyramine can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Cholestyramine.Approved
PhenprocoumonCholestyramine can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PhenylbutazoneCholestyramine can cause a decrease in the absorption of Phenylbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PimecrolimusCholestyramine can cause a decrease in the absorption of Pimecrolimus resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PiretanideCholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PirfenidoneCholestyramine can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PiroxicamCholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PirprofenCholestyramine can cause a decrease in the absorption of Pirprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazideCholestyramine can cause a decrease in the absorption of Polythiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PranoprofenCholestyramine can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
PrasteroneCholestyramine can cause a decrease in the absorption of Prasterone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Prasterone sulfateCholestyramine can cause a decrease in the absorption of Prasterone sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Cholestyramine.Approved
PrednicarbateCholestyramine can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PrednisoloneCholestyramine can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PrednisoneCholestyramine can cause a decrease in the absorption of Prednisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PregnenoloneCholestyramine can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
ProglumetacinCholestyramine can cause a decrease in the absorption of Proglumetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PropacetamolCholestyramine can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Cholestyramine.Approved, Investigational
PropyphenazoneCholestyramine can cause a decrease in the absorption of Propyphenazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ProquazoneCholestyramine can cause a decrease in the absorption of Proquazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ProscillaridinCholestyramine can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PTC299Cholestyramine can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneCholestyramine can cause a decrease in the absorption of Quinethazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RaloxifeneCholestyramine can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ResveratrolCholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
RimexoloneCholestyramine can cause a decrease in the absorption of Rimexolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RofecoxibCholestyramine can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
RonifibrateCholestyramine can cause a decrease in the absorption of Ronifibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RosiglitazoneThe serum concentration of Rosiglitazone can be decreased when it is combined with Cholestyramine.Approved, Investigational
SalicylamideCholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Salicylic acidCholestyramine can cause a decrease in the absorption of Salicylic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
SalsalateCholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SemapimodCholestyramine can cause a decrease in the absorption of Semapimod resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SeratrodastCholestyramine can cause a decrease in the absorption of Seratrodast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SerrapeptaseCholestyramine can cause a decrease in the absorption of Serrapeptase resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SimfibrateCholestyramine can cause a decrease in the absorption of Simfibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SpironolactoneThe risk or severity of adverse effects can be increased when Cholestyramine is combined with Spironolactone.Approved
SRT501Cholestyramine can cause a decrease in the absorption of SRT501 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
SulfasalazineCholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulindacCholestyramine can cause a decrease in the absorption of Sulindac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SuprofenCholestyramine can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
SuxibuzoneCholestyramine can cause a decrease in the absorption of Suxibuzone resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Cholestyramine.Approved
TarenflurbilCholestyramine can cause a decrease in the absorption of Tarenflurbil resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TenidapCholestyramine can cause a decrease in the absorption of Tenidap resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TenoxicamCholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TepoxalinCholestyramine can cause a decrease in the absorption of Tepoxalin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
TeriflunomideThe serum concentration of Teriflunomide can be decreased when it is combined with Cholestyramine.Approved
Tiaprofenic acidCholestyramine can cause a decrease in the absorption of Tiaprofenic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TinoridineCholestyramine can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
TioclomarolCholestyramine can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TixocortolCholestyramine can cause a decrease in the absorption of Tixocortol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tolfenamic AcidCholestyramine can cause a decrease in the absorption of Tolfenamic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TolmetinCholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TorasemideCholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TranilastCholestyramine can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriamcinoloneCholestyramine can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TribenosideCholestyramine can cause a decrease in the absorption of Tribenoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
TrichlormethiazideCholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TriptolideCholestyramine can cause a decrease in the absorption of Triptolide resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
UlobetasolCholestyramine can cause a decrease in the absorption of Ulobetasol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Cholestyramine.Approved, Investigational
ValdecoxibCholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational, Withdrawn
VancomycinThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Cholestyramine.Approved
WarfarinCholestyramine can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZaltoprofenCholestyramine can cause a decrease in the absorption of Zaltoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ZileutonCholestyramine can cause a decrease in the absorption of Zileuton resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ZomepiracCholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Food Interactions
  • Take with food, do not mix with soft drinks.

References

Synthesis Reference

Moh. S. Amer, Jack C. Gray, "Cholestyramine compositions and method for preparation thereof." U.S. Patent US4895723, issued March, 1967.

US4895723
General References
Not Available
External Links
PubChem Substance
46506251
ChEMBL
CHEMBL1201625
PharmGKB
PA448974
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cholestyramine
ATC Codes
C10AC01 — Colestyramine
AHFS Codes
  • 24:06.04 — Bile Acid Sequestrants
MSDS
Download (74.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDisseminated Sclerosis1
1CompletedBasic ScienceImpaired Renal Function1
1CompletedTreatmentAlagille Syndrome / Orphan Cholestatic Liver Diseases / Primary Biliary Cirrhosis (PBC) / Progressive Familial Intrahepatic Cholestasis (PFIC)1
2Active Not RecruitingTreatmentHigh Blood Cholesterol Level1
2CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Hypercholesterolemia, Familial / Myocardial Infarction (MI) / Myocardial Ischemia1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia2
3CompletedTreatmentDisseminated Sclerosis1
3RecruitingTreatmentGraves Diseases / Hyperthyroidism1
4CompletedTreatmentHealthy Volunteers2
4RecruitingTreatmentDiabetes Mellitus (DM) / Diabetic Neuropathies / Retinopathy, Diabetic1
Not AvailableCompletedTreatmentGraves Diseases1
Not AvailableRecruitingBasic ScienceHyperlipidemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Kit; powderOral4 g
Powder, for suspensionOral4 g/9g
Powder, for suspensionOral4 g
Powder, for suspensionOral4 g/5g
Powder, for suspensionOral4 g/5.5g
Powder, for suspensionOral4 g/5.7g
Powder; suspensionOral4 g
Powder, for suspensionOral400 g
Powder, for solutionOral400 g
PowderOral4 g
Powder, for solutionOral4 g
TabletOral1 g
Prices
Unit descriptionCostUnit
Questran Light 4 gm/dose Powder 210 gm Can116.3USD can
Questran 4 gm/dose Powder 378 gm Can115.62USD can
Questran Light 4 gm/dose Powder 268 gm Can102.35USD can
Cholestyramine 4 gm/dose Powder 378 gm Can57.99USD can
Cholestyramine Light 4 gm/dose Powder 210 gm Can57.99USD can
Cholestyramine resin powder16.83USD g
Questran 4 gm Packets4.4USD packet
Questran light packet4.25USD each
Questran packet4.23USD each
Cholestyramine 4 gm Packets3.5USD packet
Cholestyramine Light 4 gm Packets3.49USD packet
Cholestyramine light packet3.35USD each
Prevalite packet2.58USD each
Pms-Cholestyramine Light 4 g Powder Packet1.41USD packet
Pms-Cholestyramine Regular 4 g Powder Packet1.41USD packet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

1. Bile acids
Kind
Group
Organism
Human
Pharmacological action
Yes
Actions
Binder
References
  1. Nichifor M, Cristea D, Mocanu G, Carpov A: Aminated polysaccharides as bile acid sorbents: in vitro study. J Biomater Sci Polym Ed. 1998;9(6):519-34. [PubMed:9659597]
  2. Benson GM, Alston DR, Hickey DM, Jaxa-Chamiec AA, Whittaker CM, Haynes C, Glen A, Blanchard S, Cresswell SR, Suckling KE: SK&F 97426-A: a novel bile acid sequestrant with higher affinities and slower dissociation rates for bile acids in vitro than cholestyramine. J Pharm Sci. 1997 Jan;86(1):76-81. [PubMed:9002463]

Drug created on July 24, 2007 12:41 / Updated on January 14, 2018 10:04